T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

Trends in Immunology

Volumn 31, Issue 1, 2010, Pages 7-17

  Appel, Stanley H ^a   Beers, David R ^a   Henkel, Jenny S ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; GLUTAMIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NITRIC OXIDE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL POPULATION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; NERVE FIBER TRANSECTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; T LYMPHOCYTE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL COMMUNICATION; MICE; MICROGLIA; PARKINSON DISEASE; T-LYMPHOCYTES;

EID: 73149116008     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.09.003     Document Type: Review

References (94)

1. Carson M.J., et al. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213 (2006) 48-65
2. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
3. Boillée S., et al. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52 (2006) 39-59
4. Langston J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
5. Dauer W., and Przedborski S. Parkinson's disease: Mechanisms and Models. Neuron 39 (2003) 889-909
6. Clement A.M., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003) 113-117
7. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
8. Ransohoff R.M., and Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27 (2009) 119-145
9. Geissmann F., et al. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 86 (2008) 398-408
10. Martinez F.O., et al. Macrophage activation and polarization. Front. Biosci. 13 (2008) 453-461
11. Benoit M., et al. Macrophage polarization in bacterial infections. J. Immunol. 181 (2008) 3733-3739
12. Michelucci A., et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J. Neuroimmunol. 210 (2009) 3-12
13. Koning N., et al. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J. Neuropathol. Exp. Neurol. 68 (2009) 159-167
14. McGeer P.L., et al. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76 (1988) 550-555
15. Hunot S., et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
16. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290
17. Wang X.-J., et al. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 2 (2007) 259-264
18. Liberatore G.T., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403-1409
19. Wu D.C., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 145-150
20. Le W., et al. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
21. Ambrosini E., and Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem. Res. 29 (2004) 1017-1038
22. Kalkonde Y.V., et al. Chemokines in the MPTP model of Parkinson's disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res. 1128 (2007) 1-11
23. + and mitochondrial function. Life Sci 40 (1987) 721-729
24. Lotharius J., et al. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19 (1999) 1284-1293
25. Greenamyre J.T. Glutamatergic influences on the basal ganglia. Clin. Neuropharmacol. 24 (2001) 65-70
26. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
27. Farrer M. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55 (2004) 174-179
28. Martinez-Vicente M., et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 (2008) 777-788
29. Cookson M.R. alpha-Synuclein and neuronal cell death. Mol. Neurodegener. 4 (2009) 9
30. Lee H.J., et al. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25 (2005) 6016-6024
31. Zhang W., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542
32. Gao H.M., et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28 (2008) 7687-7698
33. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119 (2009) 182-192
34. Benner E.J., et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 3 (2008) e1376
35. Verreck F.A., et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4560-4565
36. Mount M.P. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 27 (2007) 3328-3337
37. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13 (2007) 1173-1175
38. Giuliani F., et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171 (2003) 368-379
39. + regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15620-15625
40. Schwartz M., and Kipnis J.J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J. Neurol. Sci. 233 (2005) 163-166
41. Benner E.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
42. Duda P.W. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest 105 (2000) 967-976
43. Zhao W., et al. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J. Neurochem. 99 (2006) 1176-1187
44. Chen C., et al. Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation. J. Immunol. 183 (2009) 246-253
45. Burger D., et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4355-4359
46. + regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82 (2007) 1083-1094
47. + T cell subsets. J. Immunol. 182 (2009) 4137-4149
48. Haverkamp L.J., et al. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 (1995) 707-719
49. Fischer L.R., et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185 (2004) 232-240
50. Engelhardt J.I., and Appel S.H. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 47 (1990) 1210-1216
51. Engelhardt J.I., et al. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50 (1993) 30-36
52. Henkel J.S., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol 55 (2004) 221-235
53. Huang D.R., et al. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193 (2001) 713-726
54. Kerschensteiner M., et al. Neuro-immune crosstalk in CNS diseases. Neuroscience 158 (2009) 1122-1132
55. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
56. Wong P.C., et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
57. Howland D.S., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1604-1609
58. Alexianu M.E., et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57 (2001) 1282-1289
59. Henkel J.S., et al. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31 (2006) 427-437
60. + T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 15558-15563
61. Hall E.D., et al. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23 (1998) 249-256
62. Almer G., et al. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 2415-2425
63. Sasaki S., et al. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci. Lett. 291 (2000) 44-48
64. Nguyen M.D., et al. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 50 (2001) 630-639
65. Hensley, K. et al. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82, 365-374. Erratum in: J. Neurochem. 82, 1570
66. Zhao W., et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J. Neuropathol. Exp. Neurol. 63 (2004) 964-977
67. Xiao Q., et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J. Neurochem. 102 (2007) 2008-2019
68. Beers D.R., et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16021-16026
69. Boillée S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
70. Urushitani M., et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9 (2006) 108-1018
71. Zhao, W. et al. (2009) Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. (in press)
72. Ezzi S.A., et al. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 102 (2007) 170-178
73. Gruzman A., et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12524-12529
74. Henkel J.S., et al. Alternative vs. classically activated microglial phenotypes throughout disease in the ALS mouse model. Soc. for Neurosci. Abstr (2009) Book 2, p30, 49.16
75. Chiu I.M., et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17913-17918
76. Banerjee R., et al. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE. 3 (2008) e2740
77. + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19446-19451
78. + regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 181 (2008) 2220-2226
79. + T cells to be sustained during chronic infection. J. Immunol. 179 (2007) 3926-3936
80. Schwartz M., et al. Microglial phenotype: is the commitment reversible?. Trends Neurosci. 29 (2006) 68-74
81. + T cells. Eur. J. Immunol. 34 (2004) 3434-3445
82. + regulatory T-Cells at the crossroads of health and disease. Neuromolecular Med. 7 (2005) 197-206
83. Liu Y., et al. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 12 (2006) 518-525
84. Tian L., et al. Neuronal regulation of immune responses in the central nervous system. Trends Immunol. 30 (2009) 91-99
85. Raivich G., et al. Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomized mouse facial motor nucleus and aggregate around sites of neuronal degeneration. J. Neurosci. 18 (1998) 5804-5816
86. Serpe, C.J. et al. (1999) Exacerbation of facial motoneuron loss after facial nerve transaction in severe combined immunodeficient (scid) mice. J. Neurosci. 19, RC7:1-5
87. Ha G.K., et al. Endogenous T lymphocytes and microglial reactivity in the axotomized facial motor nucleus of mice: effect of genetic background and the RAG2 gene. J. Neuroimmunol. 172 (2006) 1-8
88. + or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain Behav. Immun. 17 (2003) 393-402
89. Serpe C.J., et al. Brain-derived neurotrophic factor supports facial motoneuron survival after facial nerve transaction in immunodeficient mice. Brain Behav. Immun. 19 (2005) 173-180
90. Cahn M.Y., et al. T cell-mediated facial motoneuron survival after injury: Distribution pattern of cell death and rescue throughout the extent of the facial motor nucleus. J. Neuroimmunol. 181 (2006) 93-99
91. +) T cells. Exp. Neurol. 201 (2006) 212-224
92. Byram S.C., et al. CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation. J. Neurosci. 24 (2004) 4333-4339
93. Shaked I., et al. Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J. Neuroimmunol. 146 (2004) 84-93
94. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2 (2001) 806-819